Lianhuan Pharmaceuticals: The active pharmaceutical ingredient Levonorgestrel passed the WHO pre-qualification site inspection.

Lianhuan Pharmaceutical announced that it recently received a notification from the World Health Organization that the on-site inspection of its raw material drug product Levonorgestrel has been completed and meets the WHO good manufacturing practice standards. The inspection took place from March 10th to 13th, 2025, and included the synthesis area and some production lines in the clean area. This product is a raw material used for progestin contraceptives. The successful inspection will help maintain product quality and production capacity, but will not have a significant impact on recent performance. The main document review for its drugs has not been closed, and there is uncertainty in subsequent purchasing situations.